Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Colorectal Cancer Reports
Published in: Current Colorectal Cancer Reports 1/2017

01-02-2017 | Hot Topic

Multidisciplinary Management of Rectal Cancer with Synchronous Resectable Liver Metastases

Authors: Nishi Kothari, Daniel A. Anaya

Published in: Current Colorectal Cancer Reports | Issue 1/2017

Login to get access

Abstract

Liver metastases are the most common manifestation of metastatic disease in colorectal cancer, and synchronous metastases occur in around 50% of patients. In rectal cancer, this presentation is uniquely challenging because of issues related to competing treatments and sequencing of therapy. Though there is published data on the management of rectal tumor and liver metastasis from colorectal cancer (CRC) individually, data on the management of synchronous disease is sparse. This is a heterogeneous group of patients and should be managed on a case by case basis and with multidisciplinary evaluation. To this end, we present four cases that highlight several of the issues associated with the management presenting with resectable synchronous liver metastasis from rectal cancer.
Literature
1.
2.
Siegel R, Ward E, Brawley O, et al. The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. Ca-a Cancer J Clin. 2011;61:212–36.CrossRef
3.
Jemal A, Simard EP, Dorell C, et al. Annual report to the nation on the status of cancer, 1975–2009, featuring the burden and trends in human papillomavirus (HPV)-associated cancers and HPV vaccination coverage levels. J Natl Cancer Instit:djs491, 2013.
4.
Fernandez FG, Drebin JA, Linehan DC, et al. Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET). Ann Surg. 2004;240:438–50.CrossRefPubMedPubMedCentral
5.
Reddy SK, Zorzi D, Lum YW, et al. Timing of multimodality therapy for resectable synchronous colorectal liver metastases: a retrospective multi-institutional analysis. Ann Surg Oncol. 2009;16:1809–19.CrossRefPubMed
6.
Adam R, Pascal G, Castaing D, et al. Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases? Ann Surg. 2004;240:1052–64.CrossRefPubMedPubMedCentral
7.
• Viganò L, Capussotti L, De Rosa G, et al. Liver resection for colorectal metastases after chemotherapy: impact of chemotherapy-related liver injuries, pathological tumor response, and micrometastases on long-term survival. Ann Surg. 2013;258:731–42. Retrospective study describing tumor features such as TRG as well as liver damage that may have an effect on survival.
8.
Shindoh J, Loyer EM, Kopetz S. Optimal morphologic response to preoperative chemotherapy: an alternate outcome end point before resection of hepatic colorectal metastases. J Clin Oncol:JCO. 2012;45:2854.
9.
AlGizawy SM, Essa HH, Ahmed BM. Chemotherapy alone for patients with stage II/III rectal cancer undergoing radical surgery. Oncologist. 2015;20:752–7.CrossRefPubMedPubMedCentral
10.
•• Schrag D, Weiser MR, Goodman KA, et al. Neoadjuvant chemotherapy without routine use of radiation therapy for patients with locally advanced rectal cancer: a pilot trial. J Clin Oncol. 2014;32:513–8. Pilot study showing that selected patients with rectal cancer may not need radiation.
11.
Allen PJ, Kemeny N, Jarnagin W, et al. Importance of response to neoadjuvant chemotherapy in patients undergoing resection of synchronous colorectal liver metastases. J Gastrointest Surg. 2003;7:109–17.CrossRefPubMed
12.
Rödel C, Martus P, Papadoupolos T, et al. Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol. 2005;23:8688–96.CrossRefPubMed
13.
Rubbia-Brandt L, Giostra E, Brezault C, et al. Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery. Ann Oncol. 2007;18:299–304.CrossRefPubMed
14.
Fernandez FG, Ritter J, Goodwin JW, et al. Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases. J Am Coll Surg. 2005;200:845–53.CrossRefPubMed
15.
Masi G, Loupakis F, Pollina L, et al. Long-term outcome of initially unresectable metastatic colorectal cancer patients treated with 5-fluorouracil/leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) followed by radical surgery of metastases. Ann Surg. 2009;249:420–5.CrossRefPubMed
16.
Ychou M, Rivoire M, Thezenas S, et al. A randomized phase II trial of three intensified chemotherapy regimens in first-line treatment of colorectal cancer patients with initially unresectable or not optimally resectable liver metastases. the METHEP trial. Ann Surg Oncol. 2013;20:4289–97.CrossRefPubMed
17.
Rubbia-Brandt L, Audard V, Sartoretti P, et al. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol. 2004;15:460–6.CrossRefPubMed
18.
Vauthey J-N, Pawlik TM, Ribero D, et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol. 2006;24:2065–72.CrossRefPubMed
19.
Kooby DA, Fong Y, Suriawinata A, et al. Impact of steatosis on perioperative outcome following hepatic resection. J Gastrointest Surg. 2003;7:1034–44.CrossRefPubMed
20.
Ribero D, Wang H, Donadon M, et al. Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin‐based chemotherapy for colorectal liver metastases. Cancer. 2007;110:2761–7.CrossRefPubMed
21.
22.
Aussilhou B, Dokmak S, Faivre S, et al. Preoperative liver hypertrophy induced by portal flow occlusion before major hepatic resection for colorectal metastases can be impaired by bevacizumab. Ann Surg Oncol. 2009;16:1553–9.CrossRefPubMed
23.
Folprecht G, Gruenberger T, Bechstein WO, et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol. 2010;11:38–47.CrossRefPubMed
24.
• Primrose J, Falk S, Finch-Jones M, et al. Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the new EPOC randomised controlled trial. Lancet Oncol. 2014;15:601–11. Randomized controlled trial evaluating the role of cetuximab in resectable liver disease in CRC patients.CrossRefPubMed
25.
Khatri VP, Petrelli NJ, Belghiti J. Extending the frontiers of surgical therapy for hepatic colorectal metastases: is there a limit? J Clin Oncol. 2005;23:8490–9.CrossRefPubMed
26.
Malik H, Hamady Z, Adair R, et al. Prognostic influence of multiple hepatic metastases from colorectal cancer. Europ J Surg Oncol (EJSO). 2007;33:468–73.CrossRef
27.
Pulitanò C, Bodingbauer M, Aldrighetti L, et al. Liver resection for colorectal metastases in presence of extrahepatic disease: results from an international multi-institutional analysis. Ann Surg Oncol. 2011;18:1380–8.CrossRefPubMed
28.
Brouquet A, Mortenson MM, Vauthey J-N, et al. Surgical strategies for synchronous colorectal liver metastases in 156 consecutive patients: classic, combined or reverse strategy? J Am Coll Surg. 2010;210:934–41.CrossRefPubMed
29.
Martin RC, Augenstein V, Reuter NP, et al. Simultaneous versus staged resection for synchronous colorectal cancer liver metastases. J Am Coll Surg. 2009;208:842–50.CrossRefPubMed
30.
Nordlinger B, Sorbye H, Glimelius B, et al. A randomized phase II trial of three intensified chemotherapy regimens in first-line treatment of colorectal cancer patients with initially unresectable or not optimally resectable liver metastases. Lancet Oncol. 2013;14:1208–15.CrossRefPubMed
31.
Ychou M, Hohenberger W, Thezenas S, et al A randomized phase III study comparing adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer. Ann Oncol:mdp236, 2009.
32.
Meyerhardt JA, Mangu PB, Flynn PJ, et al. Follow-up care, surveillance protocol, and secondary prevention measures for survivors of colorectal cancer: American Society of Clinical Oncology clinical practice guideline endorsement. J Clin Oncol. 2013;31:4465–70.CrossRefPubMed
33.
Bujko K, Nowacki M, Nasierowska‐Guttmejer A, et al. Long‐term results of a randomized trial comparing preoperative short‐course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg. 2006;93:1215–23.CrossRefPubMed
34.
Ngan SY, Burmeister B, Fisher RJ, et al. Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group trial 01.04. J Clin Oncol. 2012;30:3827–33.CrossRefPubMed
35.
Kim JW, Kim YB, Kim N-K, et al. The role of adjuvant pelvic radiotherapy in rectal cancer with synchronous liver metastasis: a retrospective study. Radiat Oncol. 2010;5:1.CrossRef
36.
Butte JM, Gonen M, Ding P, et al. Patterns of failure in patients with early onset (synchronous) resectable liver metastases from rectal cancer. Cancer. 2012;118:5414–23.CrossRefPubMed
37.
Van Hooft JE, Van Halsema EE, Vanbiervliet G, et al. Self-expandable metal stents for obstructing colonic and extracolonic cancer: European Society of Gastrointestinal Endoscopy (ESGE) clinical guideline. Endoscopy. 2014;46:990–1053.CrossRefPubMed
38.
Folkesson J, Birgisson H, Pahlman L, et al. Swedish Rectal Cancer Trial: long lasting benefits from radiotherapy on survival and local recurrence rate. J Clin Oncol. 2005;23:5644–50.CrossRefPubMed
39.
Sauer R, Liersch T, Merkel S, et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol. 2012;30:1926–33.CrossRefPubMed
40.
Poston GJ, Adam R, Alberts S, et al. OncoSurge: a strategy for improving resectability with curative intent in metastatic colorectal cancer. J Clin Oncol. 2005;23:7125–34.CrossRefPubMed
41.
Berri RN, Abdalla EK. Curable metastatic colorectal cancer: recommended paradigms. Curr Oncol Rep. 2009;11:200–8.CrossRefPubMed
42.
Adam R, Delvart V, Pascal G, et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg. 2004;240:644–58.CrossRefPubMedPubMedCentral
43.
Anaya DA, Blazer DG, Abdalla EK. Strategies for resection using portal vein embolization: hepatocellular carcinoma and hilar cholangiocarcinoma, Seminars in interventional radiology, © Thieme Medical Publishers. 2008: 110–122.
44.
Orcutt ST, Kobayashi K, Sultenfuss M et al. Portal vein embolization as an oncosurgical strategy prior to major hepatic resection: anatomic, surgical, and technical considerations. Frontiers Surg. 2016:3.
45.
• Beal I, Anthony S, Papadopoulou A et al. Portal vein embolisation prior to hepatic resection for colorectal liver metastases and the effects of periprocedure chemotherapy. British J Radiol. 2014. Series describing liver hypertrophy with and without post-PVE chemotherapy.
46.
• Fischer C, Melstrom LG, Arnaoutakis D, et al. Chemotherapy after portal vein embolization to protect against tumor growth during liver hypertrophy before hepatectomy. JAMA Surg. 2013;148:1103–8. Retrospective data describing liver hypertrophy after PVE with chemotherapy.
Metadata
Title
Multidisciplinary Management of Rectal Cancer with Synchronous Resectable Liver Metastases
Authors
Nishi Kothari
Daniel A. Anaya
Publication date
01-02-2017
Publisher
Springer US
Published in
Current Colorectal Cancer Reports / Issue 1/2017
Print ISSN: 1556-3790
Electronic ISSN: 1556-3804
DOI
https://doi.org/10.1007/s11888-017-0346-9

Other articles of this Issue 1/2017

Current Colorectal Cancer Reports 1/2017 Go to the issue

Surgery and Surgical Innovations in Colorectal Cancer (S Huerta, Section Editor)

Current Status of the Watch-and-Wait Policy for Patients with Complete Clinical Response Following Neoadjuvant Chemoradiation in Rectal Cancer

Personalized Medicine in Colorectal Cancer (D Cunningham and EC Smyth, Section Editors)

Molecular Stratification of Colorectal Cancer: Moving from the Laboratory to Clinical Practice

Surgery and Surgical Innovations in Colorectal Cancer (S Huerta, Section Editor)

Robotic Surgery for Colon and Rectal Cancer: Current Status, Recent Advances, and Future Directions

Radiation Therapy and Radiation Therapy Innovations in Colorectal Cancer (JY Wo, Section Editor)

The Impact of Novel Radiation Treatment Techniques on Toxicity and Clinical Outcomes in Rectal Cancer

Basic Science Foundations in Colorectal Cancer (J Roper, Section Editor)

Microsatellite Instability Pathway and EMAST in Colorectal Cancer

Surgery and Surgical Innovations in Colorectal Cancer (S Huerta, Section Editor)

Current Concepts on the Distal Margin of Resection of Rectal Cancer Tumors after Neoadjuvant Chemoradiation
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits